生脉注射液联合左卡尼汀对维持性血液透析低血压和微炎症状态影响

目的 观察生脉注射液联合左卡尼汀治疗维持性血液透析低血压的疗效及对微炎症状态的影响.方法 选择维持性血液透析低血压患者30例,分别观察生脉注射液联合左卡尼汀治疗前、治疗后患者的血压变化及低血压发生频次及炎症因子(hs-CRP、IL-6、TNF-α)的变化.结果 生脉注射液联合左卡尼汀治疗后患者血透中低血压发生率较治疗前明显下降(P＜0.05);透中最低血压和透后血压在治疗后较治疗前明显改善(P＜0.01);治疗后炎症因子(hs-CRP、IL-6、TNF-α)的水平较治疗前明显降低(P＜0.01).结论 生脉注射液联合左卡尼汀治疗维持性血液透低血压病例安全有效,提高了低血压患者对透析的耐受性,同时对维持性血透患者微炎症状态有改善作用.

Influence of combination therapy with shengmai injection and levocarnitine on hypotension and micro-inflammatory during continues hemodialysis

Objectives To observe the efficacy of combination of shengmai injection and levocarnitine in the treatment of hypotension during continues hemodialysis and micro-inflammatory.Methods 30 patients who underwent continues hemodialysis were determined to accept combination therapy with shengmai injection and levocarnitine.Variability and incidence of hypotension,as well as inflammatory factors (hs-CRP,IL-6,TNF-α) were observed before and after the treatment.Results The incidence of hypotension during continues hemodialysis was reduced obviously after the treatment (P ＜ 0.05),while minimal blood pressure during hemodialysis and blood pressure after hemodialysis raised significantly after the treatment as well (P ＜0.01).Post-treatment inflammatory factors (hs -CRP,IL-6,TNF-α) also decreased compared with pre-treatment ones (P ＜ 0.01).Conclusions The combination therapy with shengmai injection and levocarnitine on hypotension during continues hemodialysis is safe and effective,which improves the tolerance of patients with hypotension on continues hemodialysis obviously.Meanwhile,the combination therapy significantly optimizes the micro-inflammatory status on patients who undergo continues hemodialysis.